Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?

Ṁ1kṀ1.1k

resolved Jan 7

Resolved

YES

ALL

The rise of GPL-1 agonists as "miracle" drugs to cure obesity, hypertension, and a myriad of social issues related to an unhealthy body mass has been nothing short of stunning -- as important as the development of AI. But we are just learning about the other potential effects of these. Will a new clinical trial at least confirm what we think we know about this class of drugs?

Get

1,000

to start trading!

🏅 Top traders

#	Trader	Total profit
1		Ṁ32
2		Ṁ26
3		Ṁ17
4		Ṁ14
5		Ṁ14

People are also trading

Will a majority government owned company introduce a new GLP-1 drug before 2040?

16% chance

Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?

2% chance

Will a large insurance company cover weight loss drugs before 2027?

91% chance

By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?

50% chance

Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027

89% chance

Will compelling evidence be published before 2027 showing that semaglutide increases income?

42% chance

[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...

Nobel Prize awarded for Ozempic (or GLP-1 drugs) by 2030?

43% chance

Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?

10% chance

Before 2033, will semaglutide be shown to improve lifespan, when prescribed to overweight people?

83% chance

Sort by:

I'm double-checking medical journals this week. It's not as straightforward as you might think. One of the two studies linked below was not published in 2024 but in 2023. Have a bit more patience, please. (Not inactive, Paper, just traveling.)